Welcome by Chairs

Giuseppe Luigi Banna (UK) & Ravindran Kanesvaran (Singapore)

Doublet or triplet in mHSPC

Neeraj Agarwal (US)

When ARSIs and chemotherapy fail in mCRPC what next

Elena Castro (Spain)

Hypofractionated & metastases-directed radiotherapy (MDRT) in mPC

Alison Tree (UK)

Open discussion & coffee break

Theragnostics in mPCa: Diagnosis and Treatment 

Gopinath Gnanasegaran (UK)

Antibody-drug conjugates and targeted therapies in UC

Simon Crabb (UK)

Today biomarkers and targets

Pasquale Rescigno (UK)

Industry Lunch Symposia

Only in presence – no CPD/CME credits

How to choose first-line therapy for mRCC

Monty Pal (USA)

When surgery should be offered in mRCC

Jeremy Teoh (Hong Kong, China)

Are prognostic scores useful for adjuvant and palliative therapy in mRCC

Sara E. Rebuzzi (Italy)

Open discussion & coffee break

Debate –Immunotherapy in adjuvant RCC and urothelial cancer – PROs

Yüksel Ürün, Ankara, Turkey

Debate – Immunotherapy in adjuvant RCC and urothelial cancer – CONs

Richard Griffiths (UK)

Barriers and opportunities to evidence in the real-world – Panel discussion

Gil Morgan (Sweden)

Closure remarks